J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...

The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.

RAAINBOW-2 is an international, double-blind, placebo-controlled Phase 3 study for the treatment of moderate to severe alopecia areata (AA) in at least 500 subjects. -- Cinainu is the first topical ...

Detailed price information for Rigel Pharmaceuticals (RIGL-Q) from The Globe and Mail including charting and trades.

As of Friday, January 09, AbCellera Biologics Inc.’s ABCL share price has surged by 6.45%, which has investors questioning if ...

Xeglyze is a pediculicide indicated for the topical treatment of head lice infestation in patients 6 months of age and older. The prescription medication was approved by the U.S. Food and Drug ...

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled ...

In 2024 and 2025, two thousand older adults received specialised care through the Geriatric Dermatology (GeriDerm) Clinic, a ...

Detailed price information for Corvus Pharma Com (CRVS-Q) from The Globe and Mail including charting and trades.

Hair loss is becoming more common for women in their 30s. The reason is more complicated than stress or styling habits.

Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for ...